Statistics for Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Total visits
| views | |
|---|---|
| Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update | 29 |
Total visits per month
| views | |
|---|---|
| June 2025 | 2 |
| July 2025 | 0 |
| August 2025 | 1 |
| September 2025 | 6 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
File Visits
| views | |
|---|---|
| Long_eficacy.pdf | 28 |
| EF7_Social_Inequality_Families.pdf | 1 |
| Cap. 8.pdf | 1 |
Top country views
| views | |
|---|---|
| United States | 9 |
| Brazil | 5 |
| Portugal | 5 |
| China | 2 |
| Germany | 2 |
| Egypt | 1 |
| Nigeria | 1 |
| Poland | 1 |
| Romania | 1 |
| Russia | 1 |
| Venezuela | 1 |